Zobrazeno 1 - 10 of 49 pro vyhledávání: '"Nathan Vastesaeger"'
1
Akademický článek
Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up
Autor: Jácome Bruges-Armas, Bruno F. Bettencourt, Ana R. Couto, Manuela Lima, Ana M. Rodrigues, Nathan Vastesaeger, Matthew A. Brown
Publikováno v: Case Reports in Rheumatology, Vol 2014 (2014)
Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD). Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are describ
Externí odkaz: https://doaj.org/article/ace663279c704685b3c86f9b39f2a8aa
Zobrazit plný text záznamu
2
An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases
Autor: Josef S. Smolen, K. Visser, Bruno Fautrel, Ronald F van Vollenhoven, Bernard Combe, Saedis Saevarsdottir, Cornelia F Allaart, Daniel Aletaha, Nathan Vastesaeger, Patrick Verschueren, Antoine Vanier
Publikováno v: Rheumatology, 59(8), 1842-1852. OXFORD UNIV PRESS
Rheumatology (Oxford, England), 59(8), 1842-1852. Oxford University Press
Rheumatology
Rheumatology, Oxford University Press (OUP), 2019, ⟨10.1093/rheumatology/kez542⟩
Objective In early RA, some patients exhibit rapid radiographic progression (RRP) after one year, associated with poor functional prognosis. Matrices predicting this risk have been proposed, lacking precision or inadequately calibrated. We developed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b08dba33a9744e2cea6333f37633d09d
http://hdl.handle.net/1887/3182948
Zobrazit plný text záznamu
3
Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial
Autor: Patrick Durez, Karel Pavelka, Maria Alicia Lazaro, Abraham Garcia-Kutzbach, Robert J. Moots, Howard Amital, Marinella Govoni, Nathan Vastesaeger
Publikováno v: CLINICAL RHEUMATOLOGY
Clinical Rheumatology, Vol. 37, no.5, p. 1417-1420 (2018)
GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis wa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57b5ebbcdc62b76ecb651729ca16f954
https://doi.org/10.1007/s10067-018-4074-6
Zobrazit plný text záznamu
4
Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort
Autor: Sumesh Kachroo, M. Govoni, Piercarlo Sarzi-Puttini, Nathan Vastesaeger, Filip Van den Bosch, Pascal Claudepierre
Publikováno v: International journal of rheumatic diseases. 22(6)
Aim: We evaluated the effects of anti-tumor necrosis factor (TNF) agents on health economics in ankylosing spondylitis (AS) patients. Methods: QUality of Life as Outcomes and its VAriation with DIsease States (QUO-VADIS) was a prospective observation
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62463ad109542cb6e75a89c1238b9475
https://pubmed.ncbi.nlm.nih.gov/30989813
Zobrazit plný text záznamu
5
Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: the QUO-VADIS study
Autor: Filip, Van den Bosch, Rene-Marc, Flipo, Jürgen, Braun, Nathan, Vastesaeger, Sumesh, Kachroo, Marinella, Govoni
Publikováno v: Clinical and experimental rheumatology. 37(2)
The QUO VADIS study evaluated disease activity and health-related quality-of-life (HRQoL) in ankylosing spondylitis (AS) patients treated with golimumab (GLM) or infliximab (IFX, originator) during routine clinical care.This prospective observational
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::899fac0e9e741e428efec4c24bcce3cc
https://pubmed.ncbi.nlm.nih.gov/30148434
Zobrazit plný text záznamu
6
Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial
Autor: Patrick Durez, Karel Pavelka, Nathan Vastesaeger, Abraham Garcia-Kutzbach, Robert J. Moots, M. Govoni, Howard Amital, Maria Alicia Lazaro
Publikováno v: Clinical Rheumatology, Vol. 37, no.7, p. 2017-2018 (2018)
GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naive patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bc984f3b4864560651b02105aaf6f39
https://hdl.handle.net/2078.1/220483
Zobrazit plný text záznamu
8
OP0247 An improved matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases
Autor: Patrick Verschueren, Nathan Vastesaeger, R. van Vollenhoven, Josef S. Smolen, Bruno Fautrel, Cornelia F Allaart, Antoine Vanier, Bernard Combe, K. Visser, Daniel Aletaha, Saedis Saevarsdottir
Publikováno v: Oral Presentations.
Background In early rheumatoid arthritis (RA), some patients exhibit rapid radiographic progression (RRP) after one year, associated with poor functional prognosis. Identifying at the time of diagnosis the characteristics predictive of RRP is of impo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b962bf016771dffa6d3298e119ee0267
https://doi.org/10.1136/annrheumdis-2017-eular.4752
Zobrazit plný text záznamu
9
Patient and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes
Autor: Bernard Combe, Ingrid Louw, Bhaskar Dasgupta, R. Yao, André D. Beaulieu, Jürgen Wollenhaupt, Patrick Durez, H. H. Weng, Verónica Wolff, Nathan Vastesaeger, Cristiano A. F. Zerbini, Hendrik Schulze-Koops, M. Govoni
Publikováno v: Arthritis Care & Research. 66:1799-1807
Rheumatoid arthritis (RA) management involves improving clinical outcomes and quality of life (QOL). Golimumab is used as add-on therapy for patients who have failed disease-modifying antirheumatic drugs (DMARDs). This GO-MORE subanalysis investigate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bebe12c8dcf65e9aa78d5fce722787d6
https://doi.org/10.1002/acr.22371
Zobrazit plný text záznamu
10
Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up
Autor: Ana Rita Couto, Nathan Vastesaeger, Bruno Filipe Bettencourt, Ana M. Rodrigues, Jácome Bruges-Armas, Manuela Lima, Matthew A. Brown
Publikováno v: Case Reports in Rheumatology
Case Reports in Rheumatology, Vol 2014 (2014)
Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD).Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are describe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f4cfac7f23fd1eb61a07f9cfd59adf
https://doi.org/10.1155/2014/536856
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje